Single-center Clinical Experience Research Articles

Single-center clinical experience of cyanoacrylate embolization method for incompetent perforating veins in treating CEAP-6 patients

ObjectiveThe most severe form of chronic venous insufficiency includes venous leg ulcers in the CEAP-6 stage. The aim of this study is to evaluate the relationship between incompetent perforator veins occluding with cyanoacrylate and closure of perforator veins and healing of venous leg ulcers in patients at the CEAP-6 stage. MethodsA total of 187 patients who underwent cyanoacrylate application to incompetent perforator veins due to venous leg ulcers from 2018 to 2021 were retrospectively reviewed. Twelve months after the procedure, patients were evaluated for perforator vein closure, ulcer diameter, and Venous Clinical Severity Scale. Receiver operating characteristic analysis was used to estimate the probability of postoperative nonocclusion of the perforating vein based on the preoperative ulcers’ diameters and the perforating veins’ mean diameters. Univariate and multivariate binary logistic regression analyses were conducted to identify the risk factors associated with incomplete closure of the perforating vein. ResultsAt the 12 months, 87.1% of patients experienced incompetent perforator veins closure, leading to complete healing of venous leg ulcers. Preoperative ulcer diameter significantly decreased from 7.20 ± 3.48 cm2 to 0.28 ± 0.77 cm2 after the procedure (P < .001). On average, 3.5 ± 1.01 perforating veins were treated, with a diameter of 4.09 ± 0.41 mm. No postoperative paresthesia or deep vein thrombosis occurred. Preoperative Venous Clinical Severity Scale scores decreased significantly from 17.85 ± 3.06 to 8.03 ± 3.53 postoperatively (P < .001). Patients with nonoccluded perforating veins had larger preoperative ulcer diameters (13.77 ± 1.78 cm2) than those with occluded perforating veins (6.24 ± 2.47 cm2; P < .001). The mean perforating vein diameter was also larger in nonoccluded perforating veins patients (4.45 ± 0.41 mm) than in occluded perforating veins patients (4.04 ± 0.38 mm; P < .001). The sensitivity, specificity, and accuracy of the preoperative ulcer diameter cutoff point of 11.25 cm2 for the possibility of postoperative nonocclusion of perforating veins were 100% each. In contrast, those for the preoperative mean perforating vein diameter cutoff point of 4.15 mm were determined as 66.7%, 79.1%, and 77.5%, respectively. The presence of diabetes mellitus increased the likelihood of incompetent perforator veins, remaining open by 3.4 times (95% confidence interval: 1.11-10.44; P = .032), whereas a 1 mm larger mean perforating vein diameter increased this likelihood by 9.36 times (95% confidence interval: 3.47-25.29; P < .001). ConclusionsThis study demonstrates that occlusion of incompetent perforator veins with cyanoacrylate is effective, safe, and associated with low complication rates in CEAP-6 patients. The findings support that cyanoacrylate occlusion of perforator veins may be a valuable option in the treatment of venous leg ulcers.

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience

Indolent lymphoma, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL), can undergo histological transformation into an aggressive subtype, typically diffuse large B-cell lymphoma (DLBCL). The prognosis of transformed lymphoma is poor. In this study, we reported the efficacy and toxicity of a combination of venetoclax, dose-adjusted rituximab or obinutuzumab, etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide (VR-DA-EPOCH or VG-DA-EPOCH) in 11 patients with biopsy-proven histology transformation into DLBCL, including 8 patients with RT and 3 with transformed FL (tFL). The study was conducted between October 2019 and March 2023 at our single center. The median age of participants at enrolment was 53 years. Six patients (85.7%, 6/7) achieved complete remission (CR) at the end of treatment. The best overall response rate (ORR) and CR rate were both 72.7%, respectively. Two patients received autologous hemopoietic stem cell transplant (ASCT) while two patients received ASCT concurrently with CAR-T therapy for consolidation. With a median follow-up of 13.5 (range, 2.4–29.8) months after enrollment, the median event-free survival, progression-free survival, and overall survival were 9.4, 11.5, and 17.5 months, respectively. Hematologic toxicities of grade ≥3 consisted of neutropenia (90.9%, 10/11), thrombocytopenia (63.6%, 7/11), and febrile neutropenia (54.5%, 6/11). In conclusion, VR-DA-EPOCH or VG-DA-EPOCH was a promising strategy to achieve an early remission, bridging to cellular therapy within this population.

Outcomes of Drug-Eluting Balloons for In-Stent Restenosis: Large Cohort Analysis and Single-Center Clinical Experience

BackgroundThe use of drug-eluting balloons (DEBs) remains clinically relevant in the contemporary era of drug-eluting stent percutaneous coronary interventions (DES-PCI), especially in the setting of in-stent restenosis (ISR). Our goal was to assess the outcomes of ISR patients in a large prospective registry. MethodsA total of 2329 consecutive patients with ISR-PCI (675 using DEB and 1654 with DES) were treated in our medical centre from 2010 to 2021. Clinical end points included mortality and major adverse cardiac events (MACE) at 1 year. Clinical outcomes were adjusted for multiple confounders. ResultsMean ages (65.9 ± 11.0 vs 66.1 ± 10.5; P = 0.73) and percentages of female patients (16.6% vs 18.2%; P = 0.353) were similar between both ISR groups. Patients treated with DEB for ISR suffered more from diabetes, hypertension, and previous myocardial infarction (P < 0.01 for all) and presented more frequently with acute coronary syndrome (40.0% vs 34.4%; P = 0.01) compared with patients treated with DES for ISR. One-year MACE was significantly higher in the DEB ISR-PCI group (23.4% vs 19.6%; P = 0.002) compared to the DES ISR-PCI group, but no significant differences in mortality were observed at 1 year between the groups. After adjustment for multiple confounders, DEB ISR-PCI was not associated with increased MACE at 1 year (P = 0.55). ConclusionsIn our large experience, patients treated with DEB for ISR-PCI have higher baseline risk and sustained increased MACE rates compared with DES ISR-PCI patients. After adjustment for confounding variables, clinical outcomes are similar between the groups at 1 year after PCI.

Early Reconstruction with Locoregional-Free Flaps in Post-COVID-19 Rhino-orbital-cerebral Mucormycosis Craniofacial Deformities: A Single-Center Clinical Experience from India.

Aim of the Study Mucormycosis is a rare invasive and fatal fungal infection and its resurgence in coronavirus disease 2019 (COVID-19) patients has been a matter of grave concern. It is essentially a medical disease, but surgical debridement of necrotic tissues is of paramount importance leading to severe craniofacial deformities. In this case series, we present our experience with the feasibility of early reconstruction after surgical debridement. Case Series As a Dedicated COVID Center (DCH), the institute received the largest population of COVID-19 mucormycosis patients from the entire eastern region of the country between May 2021 and August 2021. More than 5,000 COVID-19 were admitted out of which 218 patients were diagnosed with mucormycosis. Nine patients, seven males and two females, with a mean age of 39 years with craniofacial mucormycosis underwent debridement and early reconstructions (2-4 weeks from first debridement and start of antifungal therapy) with free and pedicled flaps. All flaps survived and showed no evidence of recurrence. The average time of the early reconstruction after surgical debridement was 1.7 weeks once the course of systemic amphotericin B was received. Conclusion After aggressive surgical resection and a short course of antifungal therapy, early reconstruction can be done safely based on clinical criteria, as long as there is no evidence of hyphae invasion on wound edges in the intraoperative pathology examination.

High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience.

The current standard for anal cancer treatment is essentially a 'one size fits all' approach where the dose of radiotherapy is similar whether the tumor is very small or very large. Trials are ongoing to evaluate dose de-escalation or escalation in localized disease depending on tumor size. The aim of the study was to assess results of a personalized approach involving dose stratification by stage and boost dose adjusted according to tumor early response. We retrospectively reviewed squamous cell anal cancer (SCAC) patients treated between 2011 and 2021 by long-course intensity-modulated radiotherapy (IMRT) and concomitant chemotherapy (CT); a sequential boost could be administered by IMRT or interventional radiotherapy (IRT) to obtain a total equivalent dose in 2 Gy (EQD2) of 54-60 Gy. We analyzed 110 patients (61% T3-4 stage, 71% node-positive). A total of 68.2% of patients received a sequential boost, mainly by IRT; median total EQD2 to primary site was 59.3 Gy. Acute ≥G3 toxicity rate was 36.4%. Median follow-up (FUP) was 35.4 months. A total of 83% of patients achieved clinical complete response (cCR); locoregional recurrence (LRR) occurred in 20.9% and distant metastases in 6.4% of cases. A total of 12.7% patients underwent salvage surgery. A total of 25.5% of patients reported ≥G2 and 4.5% ≥G3 late toxicity. The estimated 3-year overall survival, disease-free survival and colostomy-free survival were 92%, 72% and 84% respectively; 3-year-LRR was 22%. Nodal stage was associated with poorer cCR probability and higher LRR (p<0.05). Our results on a large cohort of patients with locally advanced SCAC and long FUP time confirmed the efficacy of IMRT; high local control and manageable toxicity also suggest IRT as a promising method in treatment personalization.

Reproductive and oncologic outcomes in women with non-epithelial ovarian cancer: Single center experience over 25 years.

This study aimed to present our single-center clinical experience regarding tumor clinicopathologic features, treatment modalities, and reproductive and oncologic outcomes in patients with non-epithelial ovarian cancer (NEOC) over 25 years. A total of 100 patients with clinicopathological diagnosis of NEOC who were treated at our tertiary care center between 1996 and 2022 were included in this retrospective cohort analysis study. Data on demographic, clinical and obstetric characteristics of patients at the time of initial diagnosis as well as tumor clinicopathologic features, treatment modalities, and oncological and reproductive outcomes were recorded. NEOCs involved germ cell tumors (GCTs) in 46 (46%) patients and sex cordstromal tumors (SCSTs) in 54 (54%) patients. Thirty patients with GCTs and thirty-four patients with SCSTs possessed histological subtypes with malignant features. Most patients with GCTs (37%) and SCSTs (55.6%) had FIGO Stage 1 disease at the time of initial diagnosis. Overall, 76.6% of patients in the GCT group (n=23) underwent fertility-sparing surgery (FSS), while 76.5% of the patients in the SCST group (n=26) were treated with non-fertility-sparing surgical procedures. All patients who underwent FSS and had a recurrence in their follow-up (n=4) was stage 3 patients. Seven out of 10 patients (2 patients at stage 3 and 5 patients at stage 1) who desired pregnancy delivered between 38 and 40 gestational weeks without any congenital anomaly. The prognosis was excellent in both groups, with 5-year overall survival (OS) rates of 93.5% in GCTs and 96.3% in SCST groups. The 5-year disease-free survival was 89.1% in GCTs and 94.4% in SCSTs. FSS was not associated with worse oncologic outcomes. NEOCs usually have a good prognosis because they are detected at an early stage. FSS may be indicated for women of reproductive age with early-stage NEOCs.

Fetal pulmonary valvuloplasty for pulmonary atresia with intact ventricular septum: a single-center clinical experience.

Fetal pulmonary valvuloplasty for pulmonary atresia with intact ventricular septum: a single-center clinical experience.

Patterns of multiple primaries in fortyfour cancer patients: a single-center clinical experience

Introduction. Multiple primaries are defined as the existence of more than one synchronous or metachronous cancer type in the same individual. Due to a longer follow-up time after a primary cancer diagnosis, the likelihood of detection of a second primary is also increased. We report on patterns of multiple primaries in a cohort of cancer patients from a single institution. Material and methods. We identified 44 patients with multiple primaries that were diagnosed, treated, and followed up between March 2011 and January 2022 from our prospectively maintained database at the Hatay Education and Research Hospital Cancer Unit. Results. The median follow-up time was 60 months (range; 3–103). The median time between the diagnosis of the first primary and the second primary was 29 months (range; 0–94). The median OS was 76 months (95% Cl 26.6–125.4) from the first diagnosis and 27 months (95% Cl 0.65–53.4) from the diagnosis of the second primary for the entire cohort. The first diagnosed tumor was localized in the gastrointestinal system in 43.2% of patients and 65.9% of all tumors were adenocarcinoma. The first diagnosed cancer was at an early stage (Stages I and II) in 63.6% of patients. At the staging evaluation of the second primary, 54.5% of patients were found to be in the early stage (Stages I and II) and 45.5% were found to be in the late stage (Stages III and IV). Conclusions. Our study is important as this is the largest cohort study about practical implications of managing multiple primaries. The risk of second and further primaries should be kept in mind in the active follow-up Introduction and surveillance of cancer patients.

Laparoscopic Nissen fundoplication: a five-year single-center clinical experience and results.

The current surgical approach in the treatment of hiatal hernia with gastroesophageal reflux disease is known as hernioplasty together with antireflux surgical procedures. Among the antireflux surgical treatment procedures, the most applied approach is the laparoscopic Nissen fundoplication. In this study, we aimed to examine the results and effectiveness of laparoscopic Nissen fundoplication and to share our clinical experiences. Patients who underwent laparoscopic Nissen fundoplication operation between January 2017 and January 2022 in the general surgery clinic of a tertiary healthcare center were included in the study. The clinical data, preoperative, operative, and postoperative findings and results of the cases were investigated. The mean age of the patients was 46.2 ± 14.7 years, and the female/male ratio was 1.5/1. According to the Clavien-Dindo classification system, 9.9% of the patients had grade I, and 18.3% grade II complications. The patients were followed up for a mean of 32.6 ± 14.8 months. During the follow-up, reoperation was planned in 5.6% of the patients due to recurrence. Laparoscopic Nissen fundoplication is a well-defined technique. It is a safe and effective surgical method with appropriate patient selection.

155 Spectrum Of Skin Neglected Tropical Diseases: A Single Center Clinical Experience in Morocco

Neglected tropical diseases (NTD) as defined by the WHO are a diverse group of acute and chronic conditions (parasitic, viral, bacterial) that cause substantial illness for more than one billion people globally. The aim of our study was to evaluate and describe clinical features of patients diagnosed with NTD in our center. We performed a retrospective descriptive study from January 2017 to January 2021, we included patients with severe, multifocal forms of NTD that required systemic treatments.

S597 A Single Center Clinical Experience With an Intraprocedural Cleansing System for Inadequate Bowel Preparation During Colonoscopy

S597 A Single Center Clinical Experience With an Intraprocedural Cleansing System for Inadequate Bowel Preparation During Colonoscopy

Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.

To evaluate the response to cabergoline (CBG) treatment in patients with non-functioning pituitary adenomas (NFPA). Retrospective, single tertiary care center study. A total of 44 patients were treated with 3 mg/week of CBG, 32 after surgical treatment (transsphenoidal surgery [TSS] in 27 and TC in 5 patients) and 12 as primary therapy. Mean age was 59.2 ± 12 years and 23 (52.2%) were women. Response to therapy was ascertained by serial magnetic resonance imaging. The median duration of CBG therapy was 30 months (IQR 24-48). Response to CBG therapy was defined as a greater than 20% reduction in tumor size and volume. A significant reduction in tumor size was documented in 29 patients (66%), whereas in 11 patients (25%) the tumor increased in size and in 4 (9%), it remained stable. Significant tumor shrinkage was documented in 4 (33.3%) of 12 patients treated primarily and in 23 (71.8%) of those treated secondarily. The three-year progression-free survival was 0.61. Cabergoline therapy is effective in reducing tumor growth in over two thirds of patients with NFPA, however 16% of patients will escape to this beneficial effect and will require alternative forms of treatment to halt tumor progression.

Adrenal incidentaloma, single center clinical experience

Adrenal incidentaloma, single center clinical experience

Effectiveness of Uniportal VATS as the First Line Treatment in Early Stage Empyema: A Single Center Clinical Experience

Background: Development of multiloculation and septation in complicated parapneumonic pleural effusion (PPE) may lead to difficult treatment. The studies pointed out that as fibrinolytic therapy might have the potential of complications and a time consuming character, so we should change our management strategy in such patients. In this study, we aimed to investigate whether or not uniportal video-assisted thoracoscopic surgery (UVATS) is an initial effective therapy based on clinical and radiologic manifestations. Methods: İn this retrospective study, sixty patients who underwent UVATS as the initial intervention with the diagnosis of multiloculated PPE were evaluated between 2016-2019. The patients comorbidities, ASA scores, durations of hospital stay and tube thoracostomy, rate of thoracotomy/decortication, the type of pleural fluid cell and also broad-spectrum antibiotic use, culture results, % neutrophil (NE) ratio with other biochemical parameters before and after VATS were recorded and analyzed. Results: Of the patients, 46 of them (77%) underwent UVATS and a subsequent second port incision was inserted in 14 patients,. Shortening of broad-spectrum antibiotic use after VATS was found to be statistically significant in the patients underwent early VATS (p &lt;0.05). We found a statistically significant decrease in the rate of NE % after VATS (p &lt;0.05), that is consistent with the clinical and radiological improvements. The radiological improvement was detected in 96.6% of the patients. Conclusions: We conclude that early UVATS without prior tube thoracostomy is a simple, effective and reliable method as the first-line treatment in patients with complicated PPE. It also confirms that earlier administration of UVATS and more aggressive therapy in the proper indications offers better clinical results

Modified Bentall procedure: A 15-year single-center clinical experience.

Bentall procedure is a standard technique for complete aortic root replacement but a huge challenge is postoperative bleeding. Many modifications have been proposed and the "button technique" is commonly used. With a 15-year experience, this study was to evaluate outcomes of this modified Bentall procedure. A retrospective study was performed with all patients who underwent the Bentall procedure with a button technique between 2005 and 2020. Commercially available composite grafts were used in 38 patients and self-assembled composite graft was used in 74 patients. Safety outcome was postoperative complications and long-term outcomes included overall and reoperation-free survivals. Among 112 patients, the mean age was 46.3 years and 69.6% were men. Indications for the Bentall procedure were ascending aortic aneurysm and valve regurgitation (59.8%), aortic dissection (19.6%), Marfan syndrome (17%), and endocarditis (3.6%). Three patients (2.7%) died in hospital. During a median follow-up period of 42 months, 11 patients died and 7 patients required reoperation. Overall survival and reoperation-free survival were 86.1% and 83.4% at 5 years and 86.1% and 72.6% at 10 years, respectively. The Bentall procedure with a button technique is safe and effective for aortic root replacement. Further investigations are required to improve the feasibility and effectiveness of the procedure.

Emerging Utility of Endovascular Thrombectomy for Acute Ischemic Stroke in the Philippines: A Single Center Clinical Experience

Emerging Utility of Endovascular Thrombectomy for Acute Ischemic Stroke in the Philippines: A Single Center Clinical Experience

Emerging Utility of Endovascular Thrombectomy in the Philippines: A Single-center Clinical Experience

Emerging Utility of Endovascular Thrombectomy in the Philippines: A Single-center Clinical Experience

Early Period Results in Patients Developing Pneumothorax and Pneumomediastinum Due to COVİD-19 Pneumonia: Single-Center Clinical Experience on 47 Cases

Early Period Results in Patients Developing Pneumothorax and Pneumomediastinum Due to COVİD-19 Pneumonia: Single-Center Clinical Experience on 47 Cases

Safety and efficacy of microwave ablation to treat pulmonary nodules under conscious analgosedation with sufentanil: A single-center clinical experience.

The present study was designed to evaluate the safety and efficacy of computed tomography-guided percutaneous microwave ablation (MWA) to treat pulmonary nodules under conscious analgosedation with sufentanil. February to May 2021, 124 patients with 151 pulmonary nodules were enrolled in this study. The patients underwent 124 sessions of MWA. Sufentanil (0.25 μg/kg) was injected intravenously before MWA. The technical success was 100% and no procedure-related deaths. The dosage of sufentanil was 16.6 ± 3.0 μg. The mean tumor diameter in the enrolled patients was 1.3 ± 0.8 cm. The intraoperative mean numerical rating scale (NRS) was 2.2 ± 1.7. Among the patients with NRS >3, seven patients had nodules adjacent to the pleura, while in ten patients, they were not adjacent. The mean systolic, diastolic blood pressure, and heart rate of patients were 139.1 ± 23.5 mmHg, 77.8 ± 12.3, and 76.1 ± 13.4 times/min, respectively, before sufentanil injection. The mean lowest systolic, lowest diastolic blood pressure, and lowest heart rate intraoperative were 132.9 ± 22.0 mmHg, 76.1 ± 12.1, and 74.0 ± 13.5 times/min. Twenty-six patients had mild adverse events including nausea (6.45%, 8/124), dizziness (2.42%, 3/124), vomiting(4.03%, 5/124), nausea and dizziness (2.42%, 3/124), nausea with vomiting and dizziness (2.42%, 3/124), urinary retention (1.61%, 2/124) and respiratory depression (0.81%, 1/124). Sufentanil is a feasible, safe, and effective analgesic for MWA in patients with pulmonary nodules. It can be used for clinical promotion.

Single-center Clinical Experience of Diarrhea in Patients Treated With Sorafenib Shows Rare Development of Pancreatic Atrophy

Sorafenib, a multikinase inhibitor that hinders tumor proliferation and promotes apoptosis,1,2 is approved for patients with different solid organ cancers, including thyroid, hepatocellular, and renal cell carcinoma. Treatment with sorafenib can be optimized by identifying and managing specific side effects, such as dose reduction in patients who experience diarrhea. One of the proposed mechanisms of sorafenib-induced diarrhea is pancreatic insufficiency3; pancreatic atrophy has been reported on computed tomography (CT) in patients treated with sorafenib.